|
US2018289793A1
|
|
Stable live attenuated recombinant dengue vaccine
|
|
WO2013038429A2
|
|
Novel sglt inhibitors
|
|
WO2012131710A2
|
|
Novel process for the synthesis of indoline derivatives
|
|
WO2012085936A2
|
|
Recombinant respiratory syncytial virus plasmids and vaccines
|
|
WO2012077138A1
|
|
Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
|
|
WO2012042539A2
|
|
3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
|
|
EP2615913A2
|
|
Sustained release pharmaceutical compositions comprising pregabalin
|
|
WO2011158257A1
|
|
Preparation process of fesoterodine and intermediates
|
|
WO2011151841A1
|
|
Fermentation process for streptococcus pneumoniae
|
|
WO2011101864A1
|
|
Novel process for the synthesis of phenoxyethyl derivatives
|
|
ZA201101045B
|
|
Modified release ramipril compositions and uses thereof
|
|
EP2445887A2
|
|
Novel azabicyclohexanes
|
|
KR20120027381A
|
|
Japanese encephalitis vaccine and method of manufacturing the same
|
|
AU2010250780A1
|
|
Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)
|
|
MX2011007399A
|
|
Dual release pharmaceutical suspension.
|
|
WO2010076809A2
|
|
Glp-1 analogs and uses thereof
|
|
AU2009318783A1
|
|
Novel antimicrobials
|
|
CA2741393A1
|
|
Combination vaccine with whole cell pertussis
|
|
EP2362781A1
|
|
Combination vaccine with acellular pertussis
|
|
WO2010038240A1
|
|
Pharmaceutical composition comprising nimesulide and levocetirizine
|
